Daniel Rosan

Daniel Rosan has a long and varied work experience. Daniel started their career in 2000 as a Project Coordinator for the Council for Responsible Public Investment. In 2003, they became Program Director for Public Health and Access to Capital for the Interfaith Center on Corporate Responsibility. In 2007, they became an Independent Consultant specializing in Global Health. In 2008, they were an MBA Intern for Partners in Health. From 2009 to 2013, they were a Senior Consultant for The Frankel Group (now Oliver Wyman). In 2013, they joined Biogen as a Senior Director of R&D Business Operations, and later became a Director of R&D Business Operations, Associate Director of Corporate Finance, and a founding member of the Portfolio Transformation Team. In 2019, they became Vice President of Corporate Development for Decibel Therapeutics. In 2020, they joined Synlogic, Inc. as SVP, Head of Finance & Investor Relations and Head of Corporate Finance & Investor Relations. Finally, in 2022, they will become CFO and CBO for Ascidian Therapeutics.

Daniel Rosan obtained their MBA from Harvard Business School between 2007 and 2009. Prior to that, they earned their BA in Theirtory from Vassar College between 1996 and 2000. Additionally, they hold a Lean Six Sigma Green Belt certification.